Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Cost is the single biggest barrier to GLP-1 access for most people. Understanding your options — brand vs compounded, insurance vs self-pay, different providers — can reduce your monthly cost by $700–$1,200 while maintaining clinical effectiveness.
Brand-Name Pricing
Ozempic (0.5mg–2mg, approved for type 2 diabetes): approximately $935/month without insurance. Wegovy (0.25mg–2.4mg, approved for weight management): approximately $1,349/month without insurance. Rybelsus (oral semaglutide): approximately $900/month. These prices reflect the US retail market as of early 2026. Insurance coverage varies — diabetic patients with Ozempic coverage fare best, while obesity-indicated Wegovy has more inconsistent coverage.
Compounded Semaglutide: The Accessible Alternative
Compounded semaglutide became widely available during the Ozempic/Wegovy shortage period and remains legal and available through licensed telehealth providers as of early 2026. The active ingredient is identical — semaglutide — manufactured by FDA-registered 503A and 503B compounding pharmacies under strict quality standards. Price ranges from $149/month (entry-level, lower doses) to $399/month (full 2.4mg maintenance doses). The savings over brand-name treatment amount to $700–$1,200 per month.
Top Providers in 2026
The key factors to evaluate: physician oversight (mandatory), pharmacy accreditation (503A/503B), dose flexibility (ability to titrate as needed), and price transparency. Two standout options:
Full physician consult + compounded semaglutide. Board-certified doctors, licensed pharmacy, direct shipping.
From $149/month. No insurance needed. Physician supervised, ships nationwide.
Manufacturer Savings Programs
Novo Nordisk offers a Wegovy Savings Card reducing brand-name cost to $0/month for eligible commercially-insured patients and $199/month for uninsured patients who qualify (income-based). The NovoCare program provides free medication to uninsured patients below income thresholds. These programs have eligibility restrictions and monthly caps — check NovoNordisk.com for current terms as they change frequently.
Key Questions to Ask Any Provider
Which compounding pharmacy fulfils your prescriptions, and is it 503A or 503B accredited? Does the physician review your labs and medical history before prescribing? What is the full price including consultations? How do dose increases affect pricing? Is there a minimum commitment period? Reputable providers are transparent on all these points.
Frequently Asked Questions
Q: How much does Ozempic cost without insurance?
A: Brand-name Ozempic (Novo Nordisk) costs $900–$1,000 per month without insurance in the US. Brand Wegovy (higher dose for obesity) costs $1,300–$1,400/month. Compounded semaglutide from telehealth providers costs significantly less — typically $149–$399/month — and is therapeutically equivalent. Compounded semaglutide is available without insurance and has made GLP-1 treatment accessible to a far wider population.
Q: Is compounded semaglutide as effective as Ozempic?
A: Yes — compounded semaglutide contains the identical active ingredient (semaglutide) at the same doses as brand-name Ozempic and Wegovy. Clinical pharmacokinetics are the same. The difference is that compounded versions are manufactured by licensed 503A/503B compounding pharmacies rather than Novo Nordisk, and are not FDA-approved as a finished product. Quality varies by pharmacy — always use a telehealth provider that partners with accredited compounding pharmacies and requires physician oversight.
Q: Does insurance cover Ozempic for weight loss?
A: Coverage varies significantly. Ozempic (approved for type 2 diabetes) is often covered by insurance for diabetic patients. Wegovy (approved for obesity/weight management) has inconsistent coverage — some plans cover it, many do not. Medicare did not cover GLP-1s for obesity until 2025 legislation changed this partially. The most reliable affordable route for non-diabetic patients pursuing weight loss is compounded semaglutide through a telehealth provider.
📖 Further Reading
Affiliate disclosure: Affiliate links present. We may earn a commission at no extra cost to you. See our Affiliate Disclosure.